Miyake H - Search Results

1

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.

Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Leung S, et al. Among authors: miyake h. Int J Cancer. 2001 Mar 15;91(6):846-50. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1131>3.0.co;2-y. Int J Cancer. 2001. PMID: 11275990

2

Antisense therapy: current status in prostate cancer and other malignancies.

Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Gleave M, et al. Among authors: miyake h. Cancer Metastasis Rev. 2002;21(1):79-92. doi: 10.1023/a:1020172424152. Cancer Metastasis Rev. 2002. PMID: 12400997 Review.

3

Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

Miyake H, Hara I, Kamidono S, Gleave ME. Miyake H, et al. Clin Cancer Res. 2001 Dec;7(12):4245-52. Clin Cancer Res. 2001. PMID: 11751526

4

Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model.

Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME. Zellweger T, et al. Among authors: miyake h. BJU Int. 2003 Sep;92(4):463-9. doi: 10.1046/j.1464-410x.2003.04349.x. BJU Int. 2003. PMID: 12930442

5

Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity.

Miyake H, Hara I, Kamidono S, Gleave ME. Miyake H, et al. Int J Urol. 2001 Jul;8(7):337-49. doi: 10.1046/j.1442-2042.2001.00311.x. Int J Urol. 2001. PMID: 11442654 Free article. Review.

6

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.

Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Gleave ME, et al. Among authors: miyake h. Urology. 2001 Aug;58(2 Suppl 1):39-49. doi: 10.1016/s0090-4295(01)01241-9. Urology. 2001. PMID: 11502446

7

Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME. Zellweger T, et al. Among authors: miyake h. J Pharmacol Exp Ther. 2001 Sep;298(3):934-40. J Pharmacol Exp Ther. 2001. PMID: 11504787

8

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.

Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Zellweger T, et al. Among authors: miyake h. Neoplasia. 2001 Jul-Aug;3(4):360-7. doi: 10.1038/sj.neo.7900174. Neoplasia. 2001. PMID: 11571636 Free PMC article.

9

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

10

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Among authors: miyake h. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,217 results

Search Page

Filters